Endovascular Engineering (E2) today announced an oversubscribed US$80 million series C financing co-led by Gilde Healthcare and Norwest, with participation from existing investors including Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, M&L Healthcare Investments, as well as two existing undisclosed strategic investors and a new global strategic investor.
The new financing supports commercialisation of E2’s novel Hēlo thrombectomy platform for the treatment of pulmonary embolism (PE).
E2 notes in a press release that the Hēlo platform was designed to address the limitations of legacy systems and features a patented dual-action mechanism that integrates aspiration with mechanical clot disruption. According to the company, the system delivers large-bore performance through a small-profile catheter, enabling efficient single-pass procedures. E2’s integrated platform is designed to support procedural efficiency and clinical performance as adoption of mechanical thrombectomy continues to expand.
“This is a pivotal milestone for E2 as we continue our mission to improve options for patients and physicians in the VTE [venous thromboembolism] space,” said Dan Rose, chief executive officer at E2. “We are incredibly proud of the capabilities of the Hēlo platform, and this financing enables us to build a strong commercial organisation while continuing important investments in R&D [research and development] and operations.”
